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edu (L. Hunter).A wealth of knowledge valuable to the translational research scientist is contained within the vast bio-
medical literature, but this knowledge is typically in the form of natural language. Sophisticated natu-
ral-language-processing systems are needed to translate text into unambiguous formal representations
grounded in high-quality consensus ontologies, and these systems in turn rely on gold-standard corpora
of annotated documents for training and testing. To this end, we are constructing the Colorado Richly
Annotated Full-Text (CRAFT) Corpus, a collection of 97 full-text biomedical journal articles that are being
manually annotated with the entire sets of terms from select vocabularies, predominantly from the Open
Biomedical Ontologies (OBO) library. Our efforts in building this corpus has illuminated infelicities of
these ontologies with respect to the semantic annotation of biomedical documents, and we propose
desiderata whose implementation could substantially improve their utility in this task; these include
the integration of overlapping terms across OBOs, the resolution of OBO-speciﬁc ambiguities, the integra-
tion of the BFO with the OBOs and the use of mid-level ontologies, the inclusion of noncanonical
instances, and the expansion of relations and realizable entities.
 2010 Elsevier Inc. All rights reserved.1. Introduction Substantial progress has been made in biomedical natural-lan-Ontological annotation of genes and gene products is widely
used as the basis for high-throughput data analysis, especially in
calculations of enrichment of Gene Ontology (GO) terms in sets
of differentially expressed genes [1–3]. Indeed, the stated objective
of the GO was ‘‘intended to make possible, in a ﬂexible and dy-
namic way, the annotation of homologous gene and protein se-
quences in multiple organisms using a common vocabulary that
results in the ability to query and retrieve genes and proteins based
on their shared biology’’ [4]. More sophisticated uses of formal
knowledge representations in data analysis are beginning to be
published [5], and there has been a strong movement toward for-
mal representation of biomedical knowledge in the community-
driven approach of the members of the Open Biomedical Ontolo-
gies (OBO) consortium [6].
At the same time, semantic annotation of biomedical docu-
ments toward formal representation of their encoded knowledge
is of growing importance to the biomedical research community
[7–9]. A wealth of knowledge valuable to the translational research
scientist is contained within these documents, but this knowledge
is in the form of natural language, which is far more difﬁcult for
computational systems to process than formal representations.ll rights reserved.
ada), larry.hunter@ucdenver.guage processing (NLP), much of it in automated methods for map-
ping text to terms from ontologies and other controlled
vocabularies (e.g., the unique identiﬁers of records of gene and
gene-product databases) [10–15]. The transformation of biomedi-
cal texts with their abundant synonymy, polysemy, and complex-
ity into unambiguous representations grounded in high-quality
consensus ontologies opens the potential application of powerful
computer-science methods to advance biomedical research, and
the OBOs present themselves as attractive resources for this task.
A critical prerequisite to the development of sophisticated NLP
systems able to perform this transformation are ‘‘gold-standard’’
annotated corpora, which are comprised of documents that have
been manually marked up with formal terms and relations by ex-
pert human annotators that can subsequently be used to train and
test these systems [16,17]. To this end, we are constructing the Col-
orado Richly Annotated Full-Text (CRAFT) Corpus, a collection of 97
manually annotated full-text biomedical journal articles, primarily
focused on the laboratory mouse. There have been other efforts to
create systematically annotated corpora of (typically limited as-
pects of) the biomedical literature [18–25]. However, while most
other gold-standard corpora are limited to sentences or abstracts,
we are annotating the entirety of these 97 full-text articles, exclud-
ing only references – resulting in a corpus with a total of more than
750,000 words of text. With the eight ontologies and terminologies
that are being employed in the CRAFT Corpus, the range of
biomedical concepts being marked up is much wider than in other
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ﬁed include (roughly in order of increasing granularity) subatomic
particles, atoms, molecules and their parts, biomacromolecular se-
quences (along with associated attributes and operations), cellular
components, cells, organisms, molecular functions, and biological
processes. Additionally, we are using OBOs and other controlled
terminologies ranging from approximately one thousand to
millions of terms in their entirety, thus affording a very high de-
gree of semantic richness, as opposed to using only relatively small
schemata, as most annotated corpora do. These ontologies and
terminologies are continually under development by biomedical
researchers and knowledge engineers and are widely used
throughout the biomedical ﬁeld, as opposed to many other annota-
tion schemata that are often idiosyncratic and not likely reusable
for other tasks. Furthermore, although these OBOs have been
frequently used in a variety of NLP tasks, they have not been
used in their entirety toward gold-standard semantic markup of
text.
Thus far, we have primarily completed the annotation of men-
tions of cells (using the OBO Cell Type Ontology (CL) [26]), cellu-
lar components (using the cellular-component (CC) subontology
of the OBO Gene Ontology (GO)), chemicals, chemical groups,
atoms, and subatomic particles (using the OBO Chemical Entities
of Biological Interest (ChEBI) ontology [27]), organisms (using the
NCBI taxonomy [28]), biomacromolecular sequences and their
associated attributes and operations (using the OBO Sequence
Ontology (SO) [29]), and biological processes and molecular func-
tions (using the BP and MF subontologies of the GO) in the 97 full
texts. Additionally, we are still annotating genes and gene prod-
ucts (using the unique identiﬁers of the records of the Entrez
Gene database [28]). Of these eight ontologies and terminologies,
four (GO BP, CC, MF, and ChEBI) are ofﬁcial OBO Foundry mem-
bers. Another three (CL, SO, and NCBI Taxonomy) appear in the
ofﬁcial OBO Foundry paper (in Table 1) as ‘‘initial foundry ontol-
ogies’’; it appears that these are considered candidate OBO Foun-
dry members and, since they are the most prominent OBOs
within their respective domains, they are likely to become ofﬁcial
members of the OBO Foundry. The eighth, the set of unique iden-
tiﬁers of the records of the Entrez Gene database (which is not an
ontology but can be considered a controlled vocabulary), are
being used because genes are a critical type of entity to identify
in the literature, and, since there is no OBO of species-speciﬁc
genes, we have resorted to the most prominent, widely used re-
source of species-speciﬁc gene information.
Realizing the potential for the extraction of knowledge from
biomedical documents and the application of powerful reasoning
methods to this knowledge depends in part on the adequacy ofTable 1
Counts of annotations and articles completed
thus far for the terminological annotation passes
for the CRAFT Corpus. The asterisk for Entrez
Gene indicates that this is an ongoing pass with
57 articles completed; all other counts are sums
of the respective annotations of all 97 articles of
the corpus.
Terminology # Annotations
ChEBI 15,310
CL 8289
Entrez Gene* 12,544
GO BP 23,588
GO CC 7241
GO MF 5853
NCBI Taxonomy 11,201
SO 32,498
Total 116,524the formal representations used to annotate the documents. The
OBOs were not originally developed as resources for the semantic
annotation of documents, and although the development of the
OBOs has been inﬂuenced by other use cases over the last decade,
semantic annotation of biomedical texts toward formal represen-
tation of their encoded knowledge has not been a prominent one.
Our efforts in building the CRAFT Corpus has illuminated some
areas in which the existing ontological resources have infelicities
with respect to the semantic annotation of biomedical documents,
and we propose changes to the OBOs that could substantially im-
prove their utility in this task. Though there have been publications
of domain-independent ontology desiderata [30–34], we are not
aware of any focusing on desiderata for ontologies (and especially
OBOs) toward the facilitation of semantic markup of natural-lan-
guage documents. In this paper, we particularly focus on the use
of the terms of these ontologies and terminologies toward seman-
tic annotation, as this constitutes the bulk of the annotation we
have completed thus far. (However, we are actively working to-
ward assertional annotation using relations as well.) We assert that
implementation of these desiderata would not hamper the use of
OBOs toward their primary purpose of annotating entities in bio-
medical databases. Furthermore, rather than distorting the OBOs
speciﬁcally for biomedical NLP research, the implementation of
these desiderata would also improve the overall quality of the col-
lective OBOs themselves, thus enabling their more effective use to-
ward other biomedical applications.2. Annotation methodology
Semantic markup is being manually performed by three anno-
tators with Ph.D.s in the biological sciences, each working with
one terminology at a time (with the exception of the GO BP and
MF subontologies, which are being annotated simultaneously by
one annotator). These annotators follow guidelines developed by
one of the authors (MB, referred to as the lead) to reﬂect his exten-
sive experience with the construction and use of ontologies, and
they are interactively trained to mark up the text with the con-
trolled vocabularies with the lead.
An initial automatic annotation pass was performed for most of
the terminological passes, marking up exact matches to the term
names and their exact synonyms, and their plurals. The annotators
review each of these programmatically created annotations, delet-
ing or changing them as needed and creating any missed annota-
tions. The lead then reviews the annotators’ markup, correcting
errors and adding missed annotations. Each annotator meets with
the lead approximately weekly to come to consensus over the sec-
tions of text that they had differently annotated in the previous
annotation time period.
All semantic annotation work is performed in Knowtator [35], a
tool developed for markup of text for NLP tasks and implemented
as a plugin to Protege-Frames [36]. OBOs were automatically trans-
lated from their native OBO Format [37] into a frame-based repre-
sentation, which is required for Knowtator. Single-blind IAA
statistics between the markup submitted by the annotator and that
resulting from review by the lead were generated through
Knowtator.
The articles of the corpus are also being syntactically annotated
in terms of sentence segmentation, tokenization, part-of-speech
tagging, and treebanking. Furthermore, the nouns and noun
phrases of the articles are being coreferentially annotated, and sen-
tences of the articles that are the bases for annotations of genes
and gene products of the laboratory mouse are being marked up
and correspondingly linked. However, further discussion of these
branches of the markup of the CRAFT Corpus is beyond the scope
of this paper.
Fig. 2. IAA statistics over time for the annotation passes using the GO BP and MF
(which are simultaneously being done by one annotator) for the CRAFT Corpus. The
x-axis is annotation time period (which is generally weekly), and the y-axis is
F-score.
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As an indication of the progress of the semantic annotation of
the CRAFT Corpus, we list the counts of annotations and articles
thus far completed for each of the terminologies we are using in
Table 1. To date, more than 116,000 annotations have been made
using terms from these terminologies in this corpus of 97 articles
and nearly 600,000 words. As a measure of the quality of these
annotations, we have graphed the IAA statistics of the semantic-
annotation projects over time, expressed as the F-score; Fig. 1
shows those for the ﬁve primarily completed projects (the CL, CC,
ChEBI, NCBI Taxonomy, and SO projects), and Fig. 2 presents those
for the GO BP and MF project (which has been graphed separately
to accommodate the more wide-ranging values along the x- and
y-axes, corresponding to timespan and F-scores of the project,
respectively). (IAA is not being calculated for the Entrez Gene pass
since this pass primarily entails the mapping of the mentions of
genes and gene products to database identiﬁers; the annotator is
using as input the results of a previous manual annotation pass
in which all of these mentions were annotated, and we felt this
would unfairly bias the statistics.) As can be seen from these statis-
tics, our annotators routinely achieve 90 + % agreement with the
project lead once they become familiar with the corresponding ter-
minology and the thorniest annotation issues are resolved, the sole
exception being the very challenging GO BP and MF pass (which is
discussed below). Oscillations in these ﬁgures, particularly in Fig. 2,
are largely explained by the fact that an annotator may make the
same error many times (or not) in a given article, which can
strongly affect IAA statistics. This is compounded by the fact that
a given article often has many mentions of some terms of the ter-
minology being used, and two annotators might consistently anno-
tate many mentions of a given set of terms differently, leading to a
signiﬁcant drop in IAA. One straightforward example of this is that
in one article, the lead annotated all 305 mentions of the word
‘‘olfactory’’ with the GO BP term sensory perception of smell (since
our annotation guidelines call for annotating adjectival forms of
terms, ‘‘olfactory’’ being the adjectival form of ‘‘olfaction’’, an exact
synonym of sensory perception of smell), while the annotator did
not; this one very repetitive speciﬁc type of error accounted for a
decrease in the IAA by 4.5 percentage points alone. Given that
there are many concepts that may be frequently mentioned within
a given article, this effect can be cumulative, leading to large vari-
ations in IAA.
Our IAA statistics are calculated using the results of our single-
blind annotation methodology (in that the lead can see the markup
of the initial annotator); these numbers are likely higher than
those resulting from true double-blind annotation would be. To as-Fig. 1. IAA-agreement statistics over time for the annotation passes using the SO,
GO CC, CL, NCBI Taxonomy, and ChEBI for the CRAFT Corpus. The x-axis is
annotation time period (which is generally weekly), and the y-axis is F-score.sess this bias, IAA was calculated for the SO pass of three articles in
a double-blind fashion (with the regular SO annotator and lead).
The double-blind IAA of 89.9% is very close to the single-blind
IAA 90.4% for the previous SO annotation batch, suggesting that
the lead is very consistent and that the single-blind IAAs are unli-
kely to be signiﬁcantly biased. Also, note that our criteria for anno-
tation matches are very strict, requiring exact matches for the
selected text spans and for the terms used to semantically annotate
these spans. Many of the mismatches (which lower the IAA) are
actually minor, due to small differences in the span of text selected
or in the chosen class.4. Desiderata for the Open Biomedical Ontologies for semantic
annotation
The OBOs have not been speciﬁcally developed for the semantic
annotation of natural-language biomedical documents, and in our
construction of the CRAFT Corpus, we have encountered many is-
sues in using them for this task. These range from issues speciﬁc
to one or a few terms from a given ontology to those that span
across several ontologies or are domain-independent. We have
previously presented lessons learned in using large terminologies
to semantically annotate concept1 mentions in natural-language
documents [40], concept-annotation guidelines [41], and issues we
have encountered in using the GO in particular for this purpose
[42]. Here we focus on our use of the OBOs and present six high-level
desiderata that we assert would make their use in semantic annota-
tion easier and more effective. These desiderata are empirically de-
rived from our substantial effort to use these terminologies in
their entirety to semantically mark up full-text journal articles,
resulting in over 116,000 annotations of mentioned ontological con-
cepts, and they are a distillation of what we have found to be most
difﬁcult in using these terminologies for this task. If implemented,
these recommendations would ensure that future development of
the ontologies meets the needs of not only annotation of genes
and gene products in databases but also of semantic annotation of
biomedical natural-language documents in the pursuit of knowledge
extraction and its formal representation.
First, several caveats. The OBOs are works in progress, and many
of them have limited or no funding to support their development.
The observations that follow should not be construed as criticisms1 Throughout this article, we have written in terms of concepts. We are aware of
ublished work that emphasizes that ontologies represent reality rather than
ncepts [38,39], and for those readers who subscribe to this view, ‘‘concept’’ may
e substituted with ‘‘universal’’ or ‘‘type’’ throughout.p
co
b
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much as possible. Most of the ontologies and terminologies within
the OBO Library are not ofﬁcial members of the OBO Foundry
(which is the natural locus for coordinating some desired changes),
and each OBO development team generally retains their indepen-
dence, so adoption of these suggestions may be uneven. Finally,
although these issues were uncovered by the use of the OBOs in
the semantic annotation of natural-language text, the suggestions
are intended to logically strengthen the collective ontologies and
generally heighten their utility; nothing we propose below entails
changes that we believe would be logically or ontologically
incorrect.
4.1. Integrate overlapping terms across OBOs
Although one of the principles of the OBO Foundry is that mem-
ber ontologies should be orthogonal to each other [6], a number of
OBOs do contain terms that overlap with terms in other OBOs. A
simple, obvious example is GO:cell and CL:cell, which presumably
refer to the same entity but are not connected (e.g., with the OWL
equivalentClass construct), and have different textual deﬁnitions.
(The CL developers intend to revise the deﬁnition of CL:cell to be
consistent with the GO and are advocating that OBOs that cur-
rently contain their own cell terms to instead refer to CL terms
(Alex Diehl, personal communication).) Likewise, ChEBI has a set
of terms representing biological macromolecules, which overlap
with but are not integrated with the extensive protein hierarchy
of the Protein Ontology (PRO) [43] nor with the macromolecular
terms of the SO. In Uberon [44], which is an OBO effort to unify
the various taxon-speciﬁc anatomical OBOs (e.g., those for mice,
humans, amphibians, teleost ﬁsh) into a general anatomical ontol-
ogy, the general terms (e.g., UBERON:uterine cervix) have formal
cross-references using the OBO Flat File Format tag xref to the
analogous taxon-speciﬁc terms (e.g., FMA:Cervix of uterus for hu-
mans, MA:uterine cervix for mice); however, this tag is used to re-
fer to an analogous term in another vocabulary [37], and such an
assertion appears to be underspeciﬁed. Some effort to properly
model this relationship would be valuable. For example, MA:uter-
ine cervix could be formally linked to UBERON:cervix via is_a, thus
stating that a mouse cervix is a type of cervix, along with a link to
Mus in the NCBI Taxonomy to represent the organismal source;
alternately, perhaps a more complex representation of asserted
homology among the anatomical entities represented by the terms
of Uberon and those of the taxon-speciﬁc anatomical ontologies
would be suitable.
This lack of clearly speciﬁed relationships among semantically
identical and related terms across different OBOs is problematic
for a variety of reasons. In semantic annotation of biomedical doc-
uments, ambiguities result from overlapping but not explicitly re-
lated term sets, which makes this task more difﬁcult. For example,
in ChEBI, protein polypeptide chain is a child of polypeptide, but in
the SO, the term polypeptide seems to be synonymous with
CHEBI:protein polypeptide chain. (The comment for SO:polypep-
tide states that it has been merged with ‘‘protein’’, and ‘‘protein’’
is an exact synonym.) To make things more difﬁcult, ChEBI also
has a term named protein, which seems to encompass both single
protein chains (corresponding to CHEBI:protein polypeptide chain,
SO:polypeptide, and presumably to PRO:protein) and also protein
complexes (corresponding to GO:protein complex). Even though
orthogonality is emphasized among the OBOs, there will always
probably be some overlap of concepts; what we are advocating is
a formalization of the relationships among these overlapping con-
cepts. The OBO Foundry principle of orthogonality should be
amended to require explicit relationships among terms across mul-
tiple ontologies when overlap is deemed desirable; a mechanism
such as MIREOT could be employed to avoid issues in importingand reasoning over multiple large ontologies [45]. Formally speci-
fying identity as well as other types of relationships among related
terms from different ontologies would not only make it easier to
semantically annotate documents with these terms but would also
help to reduce ambiguity for human users and facilitate computa-
tional use of multiple OBOs in a logically consistent way.
4.2. Avoid and remove general terms with context-speciﬁc meanings
Some OBOs contain terms that refer to more general concepts
than the domain of the ontology itself. A good example of this ap-
pears in the SO, which contains a subgraph with epistemological
terms such as independently_known, predicted, and validated.
These terms were created in the SO to be used in the necessary
and sufﬁcient deﬁnitions of more complex SO terms (e.g., pre-
dicted_gene is a gene that has_quality predicted), and at the time
of their creation, there were no appropriate ontologies of such
terms or an effective way to refer to terms from other OBOs (Karen
Eilbeck, personal communication). Within the SO, these terms de-
note epistemic properties of sequence features; for example, the
textual deﬁnition of predicted is an ‘‘attribute describing an unver-
iﬁed region’’, which may be appropriate to describe a predicted se-
quence feature but is not a good general deﬁnition for the term
predicted.
A context-speciﬁc deﬁnition such as this is especially problem-
atic for semantic annotation of text. Annotating only sequence-
speciﬁc mentions of the epistemic SO terms in the biomedical doc-
uments of our corpus turns out to be quite difﬁcult. We have come
across many ambiguous mentions of these epistemic concepts,
such as those that are applied to sequences but comment on their
functionalities, which are largely (but not entirely) outside of the
domain of the SO. Trying to decide whether an obvious mention
of the more general concept (e.g., ‘‘predicted’’) falls within a con-
text-speciﬁc deﬁnition is both difﬁcult and, with a well-designed
system of ontologies, unnecessary. A general ontology of these
epistemological terms could obviously be applied in many areas
outside of biological sequences, and there might be no need to
specify SO-speciﬁc subclasses. Therefore, the epistemic terms in
the SO should likely be extracted and reconstituted in an orthogo-
nal, more general epistemological ontology, perhaps merged with
the OBO Evidence Code Ontology [46]. These redeﬁned terms could
then be more widely applied, and their use in semantic annotation
would become signiﬁcantly easier, as it would eliminate the need
to decide (either by a human or by a computational system) these
ambiguous cases.
4.3. Resolve ontology-speciﬁc ambiguities
The use of an ontology in semantic annotation can also point
out semantic ambiguities within an ontology. For example, in the
GO, the nature of the MF terms (i.e., whether they represent mol-
ecule-level occurrents or realizable entities) and the relationship
of the MF terms to the BP terms appears ambiguous, and there
are many corresponding terms in these subontologies that we have
found extremely difﬁcult to consistently differentiate given a tex-
tual mention, even using their deﬁnitions and taking context into
account (e.g., BP signal transduction and MF signal transducer
activity, BP regulation of transcription and MF transcription regu-
lator activity). (There is an additional complication as to the uncer-
tain nature of the relationship between certain MF terms and
corresponding ChEBI role terms (e.g., GO:enzyme inhibitor activity
and CHEBI:enzyme inhibitor), which also involves the ﬁrst desider-
atum.) There are those within the OBO Consortium who advocate
for the MF terms to represent realizable entities, but the large
majority of terms are currently deﬁned as molecule-level occur-
rents. Furthermore, for the ﬁrst two pairs of terms presented in this
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(e.g., signal transducer activity part_of signal transduction) from
which it can be inferred that the former represent occurrents since
the latter are obviously occurrents and only occurrents can be
parts of other occurrents. However, consistently distinguishing be-
tween a regulation-of-transcription occurrent and a transcription-
regulator-activity occurrent is at the heart of the problem. To
maintain high interannotator agreement, we have had to subopti-
mally restrict annotation with the MF terms to speciﬁc lexical
forms. We assert that it is important to be able to specify whether
a gene or gene product has a speciﬁc functionality or is merely in-
volved in a higher-level process, but we assert that these overlap-
ping terms are problematic and make semantic annotation of text
very difﬁcult. In this case, we suggest a good approach would be to
create a taxonomy of participant classes of independent continu-
ants, (e.g., signal transducer, transcriptional regulator). Most di-
rectly, the MF terms could be transformed into these participant
terms. Alternately, the participant terms could be created in ChEBI,
and the MF terms could be transformed into true realizable-entity
terms (e.g., potential to transduce a signal, potential to regulate
transcription). This would enable the former to be deﬁned in terms
of the latter (e.g., CHEBI:signal transducer has_realizable_entity
GO:potential to transduce a signal), and the BP terms to formalize
their participants (e.g., GO:signal transduction has_participant
CHEBI:signal transducer). The separation of occurrents, their par-
ticipants, and realizable entities possessed by the participants
would be made clear.
An ambiguity in the use of an ontological term or term set may
also be able to be resolved through a consultation with one or more
developers of the ontology that may not necessarily entail a change
in the structure of the ontology but rather a clariﬁcation or chan-
ged deﬁnition. For example, we found it difﬁcult to consistently
annotate our documents with the GO BP term induction: Although
a given textual mention might refer to the induction of a biological
process (e.g., disease, mutation, enzyme activity, gene expression),
this GO term represents a more speciﬁc sense of biological induc-
tion (i.e., ‘‘[s]ignaling at short range between cells or tissues of dif-
ferent ancestry and developmental potential that results in one cell
or tissue effecting a developmental change in the other’’), and we
found this distinction between the former and the latter in the tex-
tual mentions frequently unclear; furthermore, there are other GO
terms with ‘‘induction’’ as a head noun (and not subsumed by
induction) that use it in the more general sense (e.g., induction
of apoptosis). A discussion with one of the GO developers, which
included evaluation of a number of examples with which we were
having trouble, signiﬁcantly helped toward clearer, more consis-
tent annotation with this term. (The developers of the GO have also
since renamed induction to developmental induction.) Many such
speciﬁc ambiguities become apparent when using an ontology for
semantic annotation of biomedical documents. Communication
with ontology developers, resulting in structural changes in the
ontology and/or deﬁnitions or simply clariﬁcations in the usage
of terms, is required before apparently ambiguous concepts can
be reliably identiﬁed in biomedical documents. Generally, the
developers of these ontologies have been quite responsive to such
queries.
4.4. Integrate the BFO and OBOs and use or create mid-level ontologies
There are already a wealth of domain-speciﬁc ontologies rele-
vant to biomedical research that are associated with the OBO
Library of ontologies; its Web page (http://obofoundry.org) lists 8
OBO Foundry ontologies and another 86 OBO Foundry candidate
ontologies and other ontologies of interest, including those cover-
ing taxon-speciﬁc anatomies and developmental stages, pheno-
types, cells and cellular components, environments, diseases andpathologies, chemical substances, macromolecular sequences,
organisms, and concepts relevant to biomedical experiments. On
the other end of the spectrum, the OBO Foundry has committed
to using the Basic Formal Ontology (BFO) as its upper ontology;
this general ontology ﬁrst divides everything into continuants
and occurrents and progressively subdivides these, but all concepts
represented in the BFO are intended to be applicable to the repre-
sentation of any domain [47]. However, linkage of the domain-
speciﬁc ontologies to the upper ontology is generally lacking.
Integrating the OBOs with the BFO can be accomplished at a
base level through formal is_a links between high-level terms of
the OBOs with the BFO (or with other OBO terms, as discussed in
the ﬁrst desideratum). One project that has implemented this is
BioTop, which is a proposed top-level biomedical ontology serving
to link domain-speciﬁc OBOs to upper ontologies (BFO and DOLCE)
[48]. However, some of these high-level terms are semantically
distant from even the most speciﬁc terms of the BFO. For example,
the BP terms of the GO suggest a mid-level (i.e., more general than
the GO, but more speciﬁc than the BFO) set of processes. For exam-
ple, GO:cell proliferation could be deﬁned as a more general ‘‘pro-
liferation’’ term (subsumed by BFO:occurrent) in which the entity
that is proliferating is a population (i.e., BFO:object_aggregate) of
cells (i.e., GO:cell/CL:cell). The verbs and their nominalizations that
appear in many BP terms (e.g., transport, regulation, detection) are
natural candidates for promotion to this mid-level ontology. Many
of the BP terms have subtleties that may be challenging to repre-
sent precisely, so this would likely not be a straightforward pro-
cess. There are many mentions of relatively general concepts in
biomedical texts, suggesting that these concepts of intermediate
abstraction are important in biomedical reasoning.
We have found it necessary to use context to consistently anno-
tate text [40]. For example, if the word ‘‘differentiate’’ refers to
GO:cell differentiation, it is annotated with this term even though
the word in the absence of context may be being used in its gen-
eral-English sense. If we were not to use context and only relied
on the text itself, an unacceptably large number of mentions of bio-
medical concepts would not be semantically annotated. The BP
term GO:biological regulation would never be used, for example,
as this phrase never appears in our corpus of 97 biomedical docu-
ments, despite the fact that lexical variants of ‘‘regulate’’ appear
951 times (making this one of the most common lexemes) in the
corpus and that the overwhelming majority of these do refer to
biological regulation (and therefore have been annotated as such,
taking context into account). However, since we consistently al-
ways take context into account, general words are sometimes
annotated with relatively speciﬁc terms; for example, ‘‘destabiliz-
ing’’ (i.e., this word by itself) has been annotated with GO:RNA
destabilization since this is the correct sense of the word in its con-
text and there is no more general destabilization term in the GO. It
would be better to be able to annotate a mention of such a general
word with a general term, provided that the biomedical sense of
the word is subsumed by the general sense of the word (as we
would expect GO:RNA destabilization to be subsumed by a more
general destabilization term). In addition to being more intuitive,
we assert that a methodology such as this would beneﬁt text-min-
ing research, as it would be easier to train systems to recognize
that ‘‘destabilizing’’ should be annotated with a general destabili-
zation term rather than with GO:RNA destabilization only in the
correct places (again, assuming that this term would be subsumed
by the more general term).
Additionally, this type of integration would aid information
extraction in that additional assertions involving concepts more
general than those represented by OBO terms may be detected.
For example, for the phrase ‘‘carbonic anhydrase...facilitates this
secretion’’, we have annotated ‘‘carbonic anhydrase’’ with GO:car-
bonate dehydratase activity (also specifying that it is a continuant)
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eral word that is not represented by any OBO term and is thus left
unannotated; thus, we have identiﬁed mentions of the concepts
carbonate dehydratase and secretion in this phrase, but the asser-
tion that carbonic dehydratase facilitates secretion is lost. If the
OBOs were integrated into a more general ontology with a term
representing facilitation, ‘‘facilitates’’ could be annotated and this
assertion could be extracted. With the expanded set of types of
assertions capable of being reliably extracted, integration of OBOs
with the BFO and with mid-level ontologies would also afford pow-
erful reasoning between these levels of abstraction.
4.5. Include noncanonical instances
Most of the OBOs are charged with representing canonical con-
tinuants and/or occurrents within their respective domains. In
using the GO to semantically annotate our corpus of biomedical
documents, we at ﬁrst attempted to limit annotation to mentions
of canonical concepts, but this turns out to be a deceptively difﬁ-
cult task. Noncanonicality in biomedical journal articles is espe-
cially frequent due to the fact that most of these articles present
and discuss experiments with organisms or components of organ-
isms that are subjected to substances, procedures, and environ-
mental conditions that they would not normally encounter.
Often, noncanonicality can only be inferred from a very careful
reading and comprehension of the text, and many other times it
is not clear at all whether a given concept mention is canonical
or not. Furthermore, both continuants and occurrents can be non-
canonical in any number of ways, and Rector has questioned
whether any real structure can be completely characterized as
‘‘normal’’ [49].
Our solution has been to annotate all mentions of the terms
from the OBOs we are using that match the term’s deﬁnition, even
those mentions that are explicitly noncanonical. For example, a
mention of a cellular proliferation is annotated even it is explicitly
noncanonical in some way, pathological, artiﬁcially induced, or
occurring outside of an organism; for example, the ‘‘proliferation’’
part of ‘‘hyper-proliferation’’ would be annotated with the term
GO:cell proliferation (assuming it is a hyper-proliferation of cells)
even though this is clearly a noncanonical proliferation. This guide-
line has signiﬁcantly eased our task of semantic annotation, which
had been greatly complicated by trying to determine the bound-
aries of canonicity. Although it does not require any but the most
subtle change on the part of the ontology developers, we suggest
that terms be considered to apply to both canonical and noncanon-
ical instances that meet the term deﬁnition (except in those cases
where such a distinction is explicit, of course, e.g., PATO:mislocal-
ised). This is consistent with the representation in the Founda-
tional Model of Anatomy, whose developers emphasize that their
ontology is one of canonical anatomy, which can then be used to
represent instantiated anatomy that differs in one or more aspects
from the idealized anatomy [50]. Similarly, anatomical structures
in the Ontology of Biomedical Reality are subdivided into canonical
anatomical structures and variant anatomical structures (setting
aside the question as to whether a structure can be entirely canon-
ical, as previously mentioned) [51].
In addition to sparing (human or computational) annotators
from having to make difﬁcult and subject decisions with regard
to canonicity, this recommendation allows those who plan to use
ontological terms to represent noncanonical instances, for exam-
ple, in automated reasoning systems. Rather than identifying an in-
stance as simply noncanonical, a knowledge representation should
explicitly identify which ontological assertions are violated by the
instance. For example, in the GO, GO:membrane is asserted to be
part_of GO:cell. However, a membrane can also be artiﬁcially sep-
arated from the cell and continue to exist as a membrane. Such amembrane would be noncanonical in that it is not part of a cell,
but it still could be canonical in other respects (e.g., molecular
composition, polarization). This approach is essentially a reframing
of default reasoning. Incorporating and reasoning with defaults
and exceptions into ontologies and knowledge bases requires rea-
soning beyond standard deduction and is a challenging endeavor,
as researched by Rector et al. [52,53]. One system that treats asser-
tions of canonical ontologies as default knowledge and enables
revocation of this default knowledge through the use of a proposed
class of relations has been implemented by Hoehndorf et al. [54].
The GO is developed in an annotation-driven way in that its terms
and assertions among the terms are continually edited to conform
as much as possible with the annotations in model-organism dat-
abases created using these terms [55]; however, for those annota-
tions that remain inconsistent with the ontology, representing and
reasoning with defaults and exceptions would be a mechanism to
formally relate them to the ontology. Note that this approach does
not require developers of canonical ontologies such as the GO to in-
clude explicitly noncanonical terms or alter in any way canonical
deﬁnitions of terms or assertions of relationships between these
terms.; however, it does warn them that users of these ontologies
might create representations of concepts that are noncanonical in
one or more ways with respect to canonically represented concepts
but still are subsumed by them.
4.6. Expand relations and realizable entities
The previous desiderata deal principally with concept annota-
tion, i.e., marking up mentions of ontological concepts with their
corresponding terms. To extract knowledge from biomedical docu-
ments, these annotated concept mentions must also be linked via
relations to create formally represented assertions, e.g., the ana-
tomical parts in which genes are expressed, the noncanonical bio-
logical processes that result in particular phenotypes, and diseases
and their treatments. In contrast to the OBOs, which have large
numbers of terms of which to make use in the annotation of these
articles, the ontology of relations is much sparser.
The OBO Relation Ontology (RO) [56] currently contains 26 ba-
sic relations, and another of the principles of the OBO Foundry is
that member ontologies use relations that are unambiguously de-
ﬁned in the manner of those in the RO. Some of the member ontol-
ogies (as well as many of the other ontologies and terminologies of
interest listed on the OBO Foundry site) already use relations out-
side of the RO within their respective ontologies, and most of these
unofﬁcial relations are not well-deﬁned. In some cases, these unof-
ﬁcial relations used in assertions linking terms could be replaced
with existing RO relations; for example, develops_from, which is
used in several of the anatomical developmental ontologies, could
likely be replaced in many cases with the ofﬁcial RO:transforma-
tion_of, the relation linking entities that change their classiﬁca-
tions but retain their identities. In other cases, new relations will
likely be needed for the assertions in these ontologies.
A particular area in which we (and others) have found the RO
insufﬁcient is in the precise representation of participants in occur-
rents in the OBO cross-products, which are an effort to create formal
necessary and sufﬁcient deﬁnitions of OBO terms using other OBO
terms and in so doing link these OBO terms [57]. For example, the
GO BP term GO:sulfur amino acid transport is formally deﬁned as
GO:transport that results_in_transport_of CHEBI:sulfur-containing
aminoacids, thus formally linking thepreviouslyunlinkedGO:sulfur
amino acid transport and CHEBI:sulfur-containing amino acids. The
participants inmany of the GO BP occurrents are represented provi-
sionally using speciﬁc relations, e.g., results_in_transport_of for
GO:transport and its subclasses (as above) and results_in_acquisi-
tion_of_features_of for GO:cell differentiation and its subclasses.
(Though such a relation such as results_in_transport_of may seem
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OBO relation; the latter links a subject occurrent to an object contin-
uant, while the former links a subtype of occurrent (a transport) to a
continuant.) If occurrents and their participants are to be directly
linked in this way (i.e., with the occurrent as the subject term and
the participant as the object term, directly linkedwith one relation),
then these speciﬁc relations are often needed: has_participant can-
not be used to indicate these speciﬁc roles of these participants, as
many biomedical occurrents (particularly higher-level ones, such
as those at the cellular or anatomical level) may have any number
of participants. Thus, while using has_participant would result in a
necessary assertion, it would not be sufﬁcient since a given continu-
ant may participate in any number of occurrents. Therefore, the
cross-products deﬁning GO BP terms in terms of other OBO partici-
pant terms are currently using a number of speciﬁc relations outside
of the RO.
Another option in deﬁning occurrents in terms of its partici-
pants is through the use of has_participant assertions that link
the occurrent to each input participant in which the participant
realizes some BFO:realizable_entity. In this approach, there would
likely be a need for only a few new relations linking occurrents,
their participants, and their realizable entities. More speciﬁc clas-
ses of realizable entities could be used as well, since the BFO al-
ready divides these into BFO:disposition, BFO:function, and
BFO:role; however, we have had considerable difﬁculty in distin-
guishing among realizable entities. The speciﬁcity in this represen-
tation is pushed from the relations to the realizable entities, so
there would be a need instead for speciﬁc (named or anonymous)
classes of realizable entities.
We assert that the precise representation of participant continu-
ants in occurrents is crucial for the annotation of concept mentions
and knowledge extraction from biomedical documents since there
are so many mentions of occurrents and their participants in text,
ranging from the molecular level (e.g., alanine biosynthesis) to the
cellular-component level (e.g., membrane budding) to the cellular
level (e.g., cell cycle) to the organ/organ-system level (e.g., lung
development) to the organismal level (e.g., behavior), each which
their own set of participants. In addition to these canonical occur-
rents, biomedical documents contain frequent mentions of nonca-
nonical/abnormal occurrents (e.g., increased growth) and
pathological occurrents (e.g., tumorigenesis) that are often of signif-
icant interest in translational research and that have their own sets
of participants. However, even though we have focused on occur-
rents and their participants here, we assert there is a need for addi-
tional relations and realizable entities in other aspects as well.5. Conclusions
We have brieﬂy presented our ongoing efforts in building the
CRAFT Corpus, a collection of full-text biomedical journal articles
that are being manually annotated with the entire sets of terms
of select OBOs; this corpus is intended to serve as a gold standard
in biomedical text-mining research. We have also shown prelimin-
ary IAA statistics as measures of the quality of our efforts. From an
analysis of the various difﬁculties we have encountered in using
these OBOs for semantic annotation of the documents of our cor-
pus, we have compiled and presented six high-level desiderata
for ontologies, and particularly for OBOs, that we assert would sig-
niﬁcantly ameliorate these difﬁculties and would therefore lead to
easier and more effective semantic annotation of and knowledge
extraction from biomedical documents for the translational re-
search scientist. In addition, we assert that the implementation
of these desiderata would improve the collective ontological qual-
ity of the OBOs themselves, thus enabling their more effective use
toward other biomedical applications. The implementation ofthese desiderata would likely be long-term, challenging projects,
but we assert that they are well worth the effort.
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